Kesimpta

Ofatumumab, the active ingredient in Kesimpta, is a monoclonal antibody presented as a subcutaneous formulation for injection use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients.

GNH USA supplies Kesimpta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kesimpta is a disease‑modifying therapy that targets B‑cell activity in multiple sclerosis. - Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows disability progression. - Active secondary progressive multiple sclerosis: delays confirmed disability worsening. - Clinically isolated syndrome at high risk of conversion: may lower the likelihood of developing clinically definite MS.

Kesimpta may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory tract infections: nasopharyngitis, sinusitis. - Headache. - Fatigue. - Mild lymphopenia. - Transient fever.

Serious or Rare Side Effects: - Severe infections: opportunistic or serious bacterial infections. - Progressive multifocal leukoencephalopathy (PML). - Hepatitis B reactivation. - Severe neutropenia. - Anaphylaxis or severe hypersensitivity reactions.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential risks. - Infection screening: assess for active or latent infections, especially hepatitis B. - Immunization: administer required vaccines before starting treatment. - Monitoring: perform regular blood counts and liver function tests. - Pregnancy and lactation: discuss potential risks; use only if clearly needed. - Contraindications: avoid in patients with known hypersensitivity to ofatumumab. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ofatumumab may interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause uncontrolled infection. - Immunosuppressive chemotherapy: may exacerbate immunosuppression.

Moderate Interactions (Monitor Closely): - Antiviral agents for hepatitis B: monitor viral load. - Other disease‑modifying therapies for MS: assess additive immunosuppression. - Corticosteroids: may increase infection susceptibility.